MarginsXMarginsX
Home › Markets › Health Care › LBRX

LB Pharmaceuticals Inc (LBRX)

LBRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$42.99
-0.05% on the day
Market cap
$1.4B
Small cap
Revenue
Recent IPO: no annual report filed yet
Net income
Recent IPO: no annual report filed yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerLBRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2025
SEC CIK0001691082
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Recent IPO: no annual report filed yet.

Warning signs

Cash runway
18.0 months
$215.1M cash at September 30, 2026
Share count, 1 year
+27.9%
2025-11-06 to 2026-11-03
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$215.1M cash; operating cash flow -$35.8M a quarter.Report 2026-09-30
Shares outstanding32,363,040 (2026-11-03); 25,299,102 a year earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-10-01
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., New York, New York, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$59.1M-$64.3M$215.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$51.6M-$37.6M$283.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$19.1M-$23.3M$320.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$11.5M-$18.1M$250.2MNo debt tagsNeeds four quarters10-K 2026-03-26
Q3 2025
2025-09-30
Not filed-$3.6M-$3.4M$269.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$4.9M-$5.6MNot filedNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$5.3M-$8.1MNot filedNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$5.1M-$5.7M$23.0MNo debt tagsNeeds four quarters10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-10-01
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 146 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.4%
1 month+23.6%
3 months-2.8%
Year to date+93.2%
1 year+188.7%
From 52-week high-13.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DMRADamora Therapeutics Inc.$22.50+4.14%$1.4B
URGNUroGen Pharma Ltd.$28.10+7.33%$1.4B
TYRATyra Biosciences Inc.$19.74-1.42%$1.4B
PAHCPhibro Animal Health Corporation$35.02-2.64%$1.4B
ANABAnaptysBio Inc.$45.73-1.12%$1.4B
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
NBTXNanobiotix S.A.$28.54-6.90%$1.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier